Strategic partnership Potential growth through expansion with diagnostic service providers and hospitals, leveraging HematoLogics' niche in flow cytometry and residual disease monitoring to broaden referral networks and co-develop test panels.

Diagnostics expansion Capitalize on current capabilities in hematopathology and relapse specimen analysis to offer turnkey diagnostic workflows for oncology centers seeking standardized, high-precision residual disease monitoring.

Tech enablement Leverage existing tech stack and data capabilities to integrate with client LIMS and EHR systems, enabling seamless specimen tracking, results reporting, and dash-boarding that reduces turnaround times.

Scale opportunites With mid-market size and revenue in the tens of millions, target contract opportunities with mid- to large-sized labs and hospital networks that require specialized flow cytometry and cell sorting to enhance relapse detection services.

Brand and credibility Highlight Versiti partnership and established history since 1995 to build credibility in new markets, offering co-branded education, pilot programs, and referenceable case studies to accelerate sales cycles.